CalciMedica is trading at $0.87 (5.99% down) as investors react to ongoing Nasdaq delisting risk and a weak biotech tape.
- The company recently disclosed multiple Nasdaq noncompliance notices tied to low market value and bid price, keeping regulatory and liquidity concerns in focus.
- The broader biotech sector is down sharply in a risk-off market, adding further downward pressure to the stock.